Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

A Food and Drug Administration advisory committee is meeting Tuesday to decide whether the benefits of Merck's experimental antiviral COVID-19 pill outweigh its risks.

FDA advisers to vote Tuesday on Merck's COVID-19 pill even as interest has waned

The stock price of Merck has seen an 8% fall in a month, while it was down nearly 4% on Friday, Nov 26. This can largely be attributed to the company's recently shared data for its Covid-19 antiviral pill - Molnupiravir - which shows lower efficacy of 30% against hospitalization and death in high.

Is A Rise Imminent For Merck Stock After An 8% Fall In A Month?

AstraZeneca

The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer. The application for Lynparza covers the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients Esophageal Carcinoma

Merck's KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma

Merck & Co. Inc. MRK, -5.39% and AstraZeneca PLC AZN, -1.86% said Tuesday that their supplemental New Drug Application (sNDA) for its breast cancer treatment Lynparza has been accepted and granted priority review by the U.S. Food and Drug Administration. Lynparza's sNDA is for the adjuvant treatment of patients with BRCA-mutated, human epidermal growth factor receptor 2-negative high-risk early breast cancer who have already been treated with chemotherapy.

Merck, AstraZeneca's sNDA for breast cancer treatment granted priority review by the FDA

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Accepts Submission of sNDA for LYNPARZAas Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer; Grants Priority Review.

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review

Key advisers to the FDA are scheduled to meet Tuesday, November 30, to decide emergency use authorization to Merck & Co Inc's (NYSE: MRK) experimental pill to treat COVID-19. Members of the agency's Antimicrobial Drugs Advisory Committee will scrutinize the Company's data before voting on whether its overall benefits outweigh its risks.

FDA's AdComm Meet Tomorrow To Review Safety, Efficacy of Merck's COVID-19 Pill

Adagio Therapeutics

Pfizer

The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley analyst.

3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries

Investors appear to be reacting to a Wall Street analyst's downgrade of the pharma stock.

Why Merck Stock Is Slipping Today

Shares of Merck & Co. Inc. sank Monday, to buck the gains in the health care sector and the broader stock market, after Citi Research backed away from its bullish stance on the drug maker, citing concerns over its HIV and COVID-19 treatments.

The Ratings Game: Merck stock dives after Citi downgrades on ‘high probability' that HIV treatment will be abandoned

The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for advanced or recurrent endometrial carcinoma. The approval covers adult patients who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and are not candidates for curative surgery or radiation.

Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma

Eastman Chemical

Fortune Brands Home & Security

McCormick

Stryker

After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream.

5 Buy-Rated Blue Chip Stocks With Dividends Expected to Rise This Week

Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.

Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down

KENILWORTH, N.J. & TOKYO--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

KENILWORTH, N.J. & TOKYO--(BUSINESS WIRE)---- $MRK #MRK--European Commission Approves KEYTRUDA Plus LENVIMA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

GlaxoSmithKline

Johnson & Johnson

Robert Califf got the nod, but current acting commissioner Janet Woodcock would have made a fine choice too.

Who Would Be the Best FDA Commissioner for Biotech Investors?

Merck & Co Inc (NYSE:MRK) has released new data on its COVID antiviral tablet that suggests it is not as effective as originally hoped.   Research from its MOVe-OUT study of the drug, named Molnupiravir, found that it only reduced the risk by roughly 30% in adults at high risk for disease progression.

Merck's COVID drug not as effective as first thought

Though most Covid-19 treatment stocks are surging this morning, following news of a new Covid-19 variant , pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) is down 4.3% to trade at $78.76 at last check.

Blue-Chip Drugmaker Falls on Newest Covid Treatment Data

Merck & Co Inc (NYSE: MRK) said that its experimental COVID-19 pill, molnupiravir, reduced the risk of hospitalization and death by 30% in a study, according to data from all the patients enrolled in a late-stage study (n=1433).

Updated Data Shows Merck's Oral COVID-19 Antiviral Cuts Hospitalization, Death Risk By 30%

Merck MRK, -0.63% and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%.

Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir

Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Bayer AG

Bristol-Myers

British American Tobacco

Imperial Brands PLC

Intel

Roche Holding AG

Sanofi

Western Union

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The December 2021 Heat Map

Longeveron

Novavax

Teladoc

Could rising coronavirus cases globally see these health care stocks be put back into the limelight?

4 Hot Health Care Stocks To Watch Right Now

Gilead Sciences

Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co Inc (NYSE: MRK) have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection. The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.

Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference

News for Merck Stock (MRK)